Clinical beta

FMBM is currently in clinical beta. Content is for professional review/testing and must not replace local protocols, senior clinical judgment, or official prescribing references.

Drug Monograph

Clopidogrel

Clopidogrel

P2Y12 inhibitor (thienopyridine prodrug)

DAPTPCIACSAdult

Indication

Post-PCI DAPT β€’ ACS β€’ Recent MI / stroke (guideline windows) β€’ PAD

At a glance

INDICATIONS (CORE USE)

DAPT with aspirin after PCI/ACS; stroke/PAD selected β€” **CYP2C19** variability in high-risk PCI.

ADULT DOSE (STANDARD)

Loading **300–600 mg** (ACS/PCI context) then **75 mg daily** maintenance

MAX DOSE

600 mg load max in acute settings per protocol

Route

PO

PEDIATRIC DOSE

Not standard

Do not miss

Must-not-miss safety points

Major warning

- **Bleeding** β€” DAPT and triple therapy - **Premature discontinuation** β†’ stent thrombosis - TTP (rare)

Indications

USE IF: PCI/ACS DAPT, guideline-based stroke/PAD. AVOID IF: Active bleeding, poor compliance if stent mandates DAPT without supervision.

Primary

  • DAPT after coronary stent (with aspirin)
  • ACS management pathways

Secondary

  • Recent MI
  • Recent ischemic stroke / TIA (guideline-specific)
  • Symptomatic PAD

Dosing

STANDARD (ADULT PO)

75 mg PO daily after load per PCI protocol

ADULT DOSE

Load 300–600 mg once if ACS/PCI; maintenance 75 mg daily with aspirin per cardiology duration.

PEDIATRIC DOSE

N/A

MAX DOSE

Per institutional ACS protocol for loading

Practical Note

Check PPI choice (omeprazole CYP2C19 interaction nuance β€” institution-dependent).

Warnings

Clinical warnings

  • **Major bleeding** (GI, ICH, post-procedural) β€” higher with **DAPT**, triple therapy, renal failure, age β€” counsel early symptoms
  • **DAPT after PCI/ACS:** duration is **indication- and stent-specific** β€” **do NOT stop prematurely** without **cardiology** (premature stop β†’ **stent thrombosis**, MI, death)
  • Elective surgery after recent stent β†’ **perioperative plan** with cardiology + surgery β€” **do not** assume β€œhold all antiplatelets” is safe
  • Surgery timing
  • TTP
  • CYP2C19 poor metabolizers high-risk PCI

Adverse effects

  • Bleeding
  • bruising
  • diarrhea
  • rash

Contraindications

  • **Active major bleeding** β€” hold until controlled unless embedded in explicit procedural plan
  • **Active bleeding** with need for urgent surgery β€” coordinate with cardiology if recent stent
  • Active bleeding
  • hypersensitivity

Drug interactions

  • **Anticoagulant or NSAID added on DAPT** β†’ **bleeding risk ↑** β†’ **reassess duration** (triple therapy only when justified)
  • **Strong CYP3A4 inhibitor/inducer (ticagrelor)** or **CYP2C19 issue (clopidogrel)** β†’ **avoid or switch** per cardiology/pharmacy β€” do not ignore
  • CYP2C19 inhibitors/inducers
  • warfarin
  • NSAIDs

Special populations

Pediatrics

Not standard

Pregnancy

Limited β€” specialist; breast milk present β€” risk/benefit

Lactation

See lactation references and product labeling.

Renal impairment

No dose adjustment typical

Hepatic impairment

Active pathological bleeding β€” avoid

Elderly

Bleed risk; still used with cardiology plan

Administration

PO with or without food

Monitoring

  • Monitor: - **Coronary stent / recent PCI** β†’ **do NOT stop DAPT early** without **cardiology** β€” duration **ACS vs stable CAD** differs - **Stent / DAPT** β†’ **do NOT shorten** without cardiology β€” **ACS vs stable CAD** duration differs - **Bleeding on DAPT** β†’ **which agent to hold** β€” cardiology + surgery; platelets **do not reliably reverse** P2Y12 - **CYP2C19 LOF + high-risk PCI** β†’ consider alternative P2Y12 per cardiology - Clinical bleed surveillance on DAPT
  • Recheck: - **Planned invasive procedure in 48–72h** β†’ **pre-op antiplatelet review** with cardiology + surgery β€” document **bleed vs stent thrombosis** - **Procedure in 48–72h** β†’ **documented antiplatelet plan** β€” bleed vs stent thrombosis - New or worsening **bleeding**, unexplained **Hb drop**, or planned invasive procedure within **48–72h** β†’ reassess antiplatelet plan with cardiology/surgery when on DAPT - If targets not met after reassessment of dose, organ function, and interactions β†’ escalate per protocol (DO NOT continue blindly)
  • Hold if:
    - **Bleeding or unexplained Hb drop** β†’ **hold strategy** is team-based β€” do not stop all agents without plan

Overdose / toxicity

Clinical Picture

**A) Therapeutic complication:** **bleeding** on DAPT/triple therapy or peri-procedure β€” **no** classic β€œsupratherapeutic serum level” syndrome for oral P2Y12. **B) Massive oral overdose:** management is **supportive + bleeding care**; **no** specific antidote β€” **not** salicylate-style toxicology unless co-ingestion.

Immediate Actions

**A:** Stop P2Y12 (and often aspirin in DAPT) per **cardiology + surgery** plan β†’ mechanical hemostasis; transfuse as indicated β€” **stent timing** if interruption considered. **B:** Charcoal if very early massive ingestion + protected airway; otherwise **observe + bleed surveillance**

Antidote

No specific antidote; treat complications (supportive care, platelets / hemostasis per protocol, anaphylaxis β†’ epinephrine per ACLS)

Decontamination

**B:** Charcoal only if massive ingestion within narrow window; **A:** N/A maintenance therapy

Escalation

**ICH** or unstoppable surgical bleed β†’ **ICU**; platelet transfusion **does not fully reverse** P2Y12 β€” **procedural/heme judgment**

Clinical pearls

Common mistakes, resistance logic, and bedside traps

High-Yield Summary

**Never stop DAPT post-stent** without cardiology. β†’ CYP2C19 LOF in high-risk PCI β€” escalate therapy per lab.

Clinical pearls

Verify intended DAPT duration on discharge summary. *Antiplatelet (all agents):* **Primary vs secondary (aspirin):** primary **not routine**; secondary **strong** when guideline-supported. **DAPT:** **do not stop early** post-stent without expert; duration **ACS vs stable CAD**; procedures need **explicit review**. **Bleeding-first:** GI/ICH/peri-op; **duplicate/hidden aspirin** on med rec. **Aspirin toxicity** (salicylate) is a **separate pathway** from antiplatelet bleed.

Antiplatelet safety

  • DAPT duration
  • Bleeding signs
  • Surgery coordination

Pharmacokinetics

Prodrug; onset hours; offset ~5–7 days platelet function.

Mechanism of action

P2Y12 ADP receptor blockade (active metabolite).

Common brand names

Saudi Arabia

Plavix, Clopilet

Global

(placeholder β€” verify local product)

Common trade names are curated examples only β€” formulations and availability vary. Verify the exact product name with your local pharmacy and national regulator before prescribing or dispensing.

Country practice notes

  • DAPT duration and perioperative management follow **ESC/AHA/ACC** and local cardiology consensus β€” not one-size rules.
  • Primary prevention aspirin thresholds differ by guideline and age β€” verify regional primary-care policy.

References

Saudi Arabia

  • SFDA (Saudi Food & Drug Authority)
  • Saudi National Formulary / MOH (where available)

International

  • WHO Model List of Essential Medicines (verify current edition)
  • US FDA or EU EMA product information (when national SmPC is unavailable)
  • ACC / AHA / ESC cardiovascular guidelines (CAD, ACS, PCI)
  • FDA / SFDA product labeling
  • Local cath lab / antithrombotic protocol
  • ACC / AHA / ESC cardiovascular guidelines (CAD, ACS, PCI)
  • FDA / SFDA product labeling
  • Local cath lab / antithrombotic protocol

Do not miss

  • Document antiplatelet indication (primary vs secondary prevention vs stent DAPT)
  • Med reconciliation: OTC aspirin, NSAIDs, fish oil, anticoagulants
  • **Stent thrombosis:** Stopping DAPT early for convenience β†’ **catastrophic stent thrombosis** β€” only pause with **cardiology**-signed plan.
  • **Bleeding on DAPT (GI / access / ICH):** Do not stop both agents blindly β€” **which to hold and for how long** is **cardiology + surgery** decision; balance **peri-procedural bleed** vs **stent thrombosis**.
  • **Non-responder:** High-risk PCI + CYP2C19 LOF β†’ consider **prasugrel/ticagrelor** per cardiology β€” not empiric double dose without context.
  • Stent patient stops clopidogrel for tooth extraction without plan β†’ **thrombosis risk**.
  • **DAPT (factory rules):**
  • **Do NOT stop early** after coronary stent unless **cardiology/expert**-directed β€” premature stop β†’ **stent thrombosis**.
  • **Duration** depends on **ACS vs stable CAD/PCI** context β€” not one schedule for all.
  • **Planned procedure** β†’ **explicit antiplatelet review** with cardiology + surgery β€” document **bleed vs thrombosis** tradeoff.
  • DAPT duration
  • Bleeding signs
  • Surgery coordination